Treprostinil Delivery System Cleared to Be Prefilled at Specialty Pharmacies
Remunity is indicated for continuous subcutaneous delivery of Remodulin to treat pulmonary arterial hypertension in patients ≥22 years of age.
Pulmonary Arterial Hypertension
Anticoagulation Improves Outcomes in Idiopathic PAH, but Not CTD-PAH
Systemic anticoagulation was found to improve quality-adjusted life years among patients with idiopathic pulmonary arterial hypertension but not among those with connective tissue disease-associated pulmonary arterial hypertension.
No Causal Association Between Red Cell Distribution Width and PAH
No causal association between elevated red cell distribution width and pulmonary arterial hypertension was established.
Factors Influencing Improved Survival in Systemic Sclerosis-Associated PAH
Pulmonary arterial hypertension with systemic sclerosis associated-survival improved over time among patients aged 70 years or younger, but not among the elderly.
Cardiac MRI Could Be Useful in Pulmonary Arterial Hypertension Risk Stratification
Cardiac magnetic resonance imaging is useful for risk stratification in patients with pulmonary arterial hypertension.
Expert Consensus Survey: Prostacyclin Pathway Agent Use in Pulmonary Arterial Hypertension
A new consensus survey of expert opinions was published regarding the use of oral prostacyclin pathway agents in patients with various forms of pulmonary arterial hypertension.
Cardiopulmonary Exercise Testing Plus Screening Algorithm Useful in SSc-Related PAH
Researchers evaluated whether cardiopulmonary exercise testing could improve the performance of the DETECT screening approach in systemic sclerosis-related pulmonary arterial hypertension.
Cardiac MRI Metrics Help Stratify Mortality Risk in Pulmonary Arterial Hypertension
In patients with pulmonary arterial hypertension, cardiac magnetic resonance imaging metrics are capable of identifying individuals at a low risk for 1-year mortality.
Rapid Iloprost Inhalation Improves Pulmonary Vascular Resistance in PAH
This study assessed improvement in pulmonary vascular resistance and cardiac index in patients with pulmonary arterial hypertension who rapidly inhale iloprost 2.5 ug via the Breelib™ nebulizer.
Thinking Outside the Lungs: Extrapulmonary Manifestations in PAH
Emerging evidence suggests that the extrapulmonary effects of pulmonary arterial hypertension may manifest in the form of vascular dysfunction in systemic circulation, metabolic/endocrine dysfunction, and skeletal and respiratory muscle dysfunction.
Next post in Pulmonary Hypertension
